• Developing innovative cancer immunotherapies
  • Four lead products in development
  • Started work on a coronavirus vaccine

What the company does

AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.

Scancell Holdings PLC (LON:SCLP)  lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial in the UK.

The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D.

Inflexion points

The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).


CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.

Meanwhile, the company is already signing collaboration deals for its AvidiMab technology, having currently inked a deal with three partners, most recently a US antibody company in January.

The US firm will conduct preclinical studies to evaluate the potential for the anti-TaG mAbs developed by AvidiMab to treat cancer. A similar deal was secured with a Chinese biotech in December.

In June, Scancell published new research in a peer-reviewed journal highlighting the potential of its Modi-1 vaccine in hard-to-treat cancers.

The drug developer said the research, published in Journal for ImmunoTherapy of Cancer,  described Modi-1’s ability to stimulate potent T cell responses that translate into tumour protection in melanoma and ovarian cancer models.n There was also evidence of a memory response to protect against a return of the tumour.

In July, the company completed what it said was a “significantly oversubscribed” placing as part of plans to raise up to £15mln to support the continued initial development of a coronavirus (COVID-19) vaccine as well as clinical trials and partnering discussions for its antibody technology.


Scancell has also begun a research programme to develop a vaccine for the coronavirus.

The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to utilise the company’s clinical expertise in cancer to produce a cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against coronavirus

Initial research is now underway, with the company anticipating a phase 1 clinical trial in the first quarter of 2021.

The firm is also “actively seeking” development partners and additional partners to support rapid development of the vaccine.

What the boss says: Cliff Holloway, chief executive